Login / Signup

Small-molecule AT2 receptor agonists.

Mathias HallbergColin SumnersU Muscha SteckelingsAnders Hallberg
Published in: Medicinal research reviews (2017)
The discovery of the first selective, small-molecule ATR receptor (AT2R) agonist compound 21 (C21) (8) that is now extensively studied in a large variety of in vitro and in vivo models is described. The sulfonylcarbamate derivative 8, encompassing a phenylthiofen scaffold is the drug-like agonist with the highest affinity for the AT2R reported to date (Ki = 0.4 nM). Structure-activity relationships (SAR), regarding different biaryl scaffolds and functional groups attached to these scaffolds and with a particular focus on the impact of various para substituents displacing the methylene imidazole group of 8, are discussed. Furthermore, the consequences of migration of the methylene imidazole group and presumed structural requirements for ligands that are aimed as AT2R agonists (e.g. 8) or AT2R antagonists (e.g. 9), respectively, are briefly addressed. A summary of the pharmacological actions of C21 (8) is also presented.
Keyphrases
  • small molecule
  • tissue engineering
  • protein protein
  • multidrug resistant
  • photodynamic therapy
  • dna damage response
  • oxidative stress
  • mass spectrometry
  • drug induced
  • single cell
  • rectal cancer
  • capillary electrophoresis